公开(公告)号：US06391300B1

公开(公告)日：2002-05-21

申请号：US09192905

申请日：1998-11-16

申请人： Eric Rose ,  David Stern ,  Ann Marie Schmidt ,  Talia Spanier

发明人： Eric Rose ,  David Stern ,  Ann Marie Schmidt ,  Talia Spanier

IPC分类号： A61K3836

CPC分类号： A61M1/3675 ,  A61K38/4846 ,  G01N33/86 ,  G01N2333/9645

摘要： This invention provides a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation which comprises contacting the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient. The Factor IXa compound may include an active site-blocked Factor IXa compound or Glu-Gly-Arg chloromethyl ketone-inactivated human factor IXa compound. This invention also provides that the effective amount may be from about 0.1 &mgr;g/ml plasma to about 250 &mgr;g/ml plasma or from about 0.5 &mgr;g/ml plasma to about 25 &mgr;g/ml plasma. The patient may be subjected to extracorporeal blood circulation during transplant surgery or cardiopulmonary bypass surgery. This invention further provides for a method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal blood circulation, which comprises contacting the extracorporeal circulating blood with an agent capable of inhibiting a step of the intrinsic pathway of coagulation in an amount effective to inhibit thrombosis in the blood of a patient and under conditions such that the Factor IXa compound circulates in the patient. The agent may be an active site-blocked Factor XII compound or an active site-blocked Factor XI compound.

摘要翻译： 本发明提供了一种用于抑制血液经受体外血液循环的患者的血栓形成的方法，该方法包括使体外循环血液与因子IXa化合物以有效抑制患者血液中的血栓形成的量接触， 因子IXa化合物在患者体内循环。 因子IXa化合物可包括活性位点封闭的因子IXa化合物或Glu-Gly-Arg氯甲基酮灭活的人因子IXa化合物。 本发明还提供有效量可以为约0.1mug / ml血浆至约250mug / ml血浆或约0.5mug / ml血浆至约25mug / ml血浆。 患者可能在移植手术或心肺分流手术期间受到体外血液循环。 本发明还提供了一种用于抑制血液经受体外血液循环的患者的血栓形成的方法，其包括使体外循环血液与能够抑制凝固途径的步骤的试剂以有效抑制血栓形成的量接触 在患者的血液中和在因子IXa化合物在患者体内循环的条件下。 该试剂可以是活性位点封闭的因子XII化合物或活性位点封闭的因子XI化合物。

公开(公告)号：US5839443A

公开(公告)日：1998-11-24

申请号：US648561

申请日：1996-05-16

申请人： Eric Rose ,  David Stern ,  Ann Marie Schmidt ,  Talia Spanier

发明人： Eric Rose ,  David Stern ,  Ann Marie Schmidt ,  Talia Spanier

IPC分类号： A61K38/36 ,  A61K38/48 ,  A61M1/36 ,  G01N33/86 ,  A61B19/00

CPC分类号： A61M1/3675 ,  A61K38/4846 ,  G01N33/86 ,  G01N2333/9645

摘要： This invention provides an assay to monitor antithrombic activity of a Factor IXa compound infused into circulation of a patient which includes: (a) obtaining Factor IXa-deficient plasma; (b) mixing the plasma from step (a) with diatomaceous and with plasma from the patient; (c) incubating the mixture with a source of lipid and calcium chloride under conditions suitable for clot formation; and (d) measuring time necessary for clot formation in the incubate, thereby monitoring the antithrombic activity of the Factor IXa compound infused into the circulation of the patient.

摘要翻译： 本发明提供了监测注射到患者循环中的因子IXa化合物的抗血栓活性的测定法，其包括：（a）获得因子IXa缺陷血浆; （b）将来自步骤（a）的血浆与硅藻土和来自患者的血浆混合; （c）在适合凝块形成的条件下将混合物与脂质和氯化钙源一起孵育; 和（d）测量培养物中凝块形成所需的时间，从而监测输注到患者循环中的因子IXa化合物的抗血栓活性。